Possible Drug Target Identified for Cystic Fibrosis

Article

An age-dependent increase in ceramide levels in the lungs of mice with cystic fibrosis causes many of the symptoms of the disease, which can be reversed by an inhibitor that normalizes ceramide levels, according to research published online March 30 in Nature Medicine.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Related Content
Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more | Image Credit: © Artur - © Artur - stock.adobe.com.

Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more

Joshua Fitch, Senior Editor
June 27th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.

Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors

Joshua Fitch, Senior Editor
June 26th 2025
Article

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
ACIP updates: Committee votes 5-2 to recommend clesrovimab to protect against RSV | Image Credit: © JJHVEPhoto - © JHVEPhoto - stock.adobe.com.

ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination

Joshua Fitch, Senior Editor
June 26th 2025
Article

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis | Image credit: Weill Cornell Medicine

Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis

Andrew Alexis, MD, MPH
June 25th 2025
Article

Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.

© 2025 MJH Life Sciences

All rights reserved.